EPO can induce endothelial cell proliferation, migration, and angiogenesis through the JAK2/STAT5 signaling pathway, thus inducing the occurrence of experimental AAA, and blockade of JAK2/STAT3 suppresses the growth of AAA [63–65]. The gene discussed is JAK2; the disease is triple-A syndrome.